Shenzhen Mericonn Technology Co., Ltd. appears in FDA’s 510(k) database as the applicant for K254171, a Traditional premarket notification for four mesh nebulizer model designations. The record shows a submission received on 23 December 2025 and a substantially equivalent decision dated 18 September 2026, reviewed under the Anesthesiology panel. Mericonn’s published company profile states it was founded in 2019 and describes itself as a Class II medical device manufacturer registered with China’s National Medical Products Administration. [1][2][4][6]
The K254171 clearance and its scope
K254171 covers Mesh Nebulizer (UN204), (UN205), (UN209) and (UN210), classified as a Nebulizer (Direct Patient Interface) under 21 CFR 868.5630, device class 2, product code CAF. FDA’s record lists the decision as SESE, meaning Substantially Equivalent, with a Traditional clearance type, no third-party review and a Summary as the statement type. The submission was received 23 December 2025 and decided 18 September 2026. [1][2][6]
A summary description indexed for the record states the four models share working principle, specifications, structure, intended use and software, differing only in appearance and power configuration. UN204 and UN209 are described as powered by an internal lithium battery charged through an AC adapter, while UN205 and UN210 run on two AA batteries or directly from an AC adapter. The same indexed text gives the indication as an ultrasonic mesh nebulizer that aerosolizes liquid medication for inhalation. [5][7]
What the company says about itself
Mericonn’s About Us page states that the company was founded in 2019. It states that the company has more than 30 authorized patents at home and abroad, and describes two co-founders with over 20 years of experience. These are the manufacturer’s own corporate statements, rather than FDA findings. [4]
The company website lists mesh nebulizers, compressor nebulizers, handheld fetal dopplers, upper-arm blood pressure monitors, fingertip oximeters and baby nasal aspirators among its core products, and describes focus on Class II home medical devices with in-house research and production. A 2022 site news item states that company-developed fetal doppler and pulse oximeter products obtained FDA 510(k) clearance; the numbered sources here do not include those clearance records. [3]
Reading the filing record correctly
The linked portfolio for this snapshot contains one 510(k) record, K254171, with a decision count of one SESE. That is the extent of the supplied filing set as of 20 November 2026, not a statement of the company’s total regulatory history, sales or safety performance. The 2022 website item about fetal doppler and pulse oximeter clearances is a separate company statement and is not represented in that count. [1][3]
The FDA record identifies Shenzhen Mericonn Technology Co., Ltd. as the applicant at a Shenzhen address in Longhua District. That filing address is a regulatory contact detail and does not establish a headquarters, ownership structure or corporate parent. No parent, brand owner or affiliate relationship is verified in the numbered sources, and the manufacturer’s site presents Mericonn Medical as its own identity. [1][3][4]
Regulatory context for the device type
The K254171 record places the mesh nebulizers in FDA’s Anesthesiology review panel and marks the device attributes as therapeutic and pediatric in an indexed summary of the clearance. The record also notes a Summary statement rather than a 510(k) Statement. Predicate devices are not published in the openFDA 510(k) endpoint, so the predicate named in the summary is not asserted here. [1][7][8]

